Drug Profile
Research programme: anti-TNF-alpha therapeutics - Pharmexa
Alternative Names: Anti-TNFα vaccine - Pharmexa; Anti-tumour necrosis factor alpha vaccine - Pharmexa; AutoVac TNFα vaccine - Pharmexa; ME 101; PX 101; TNF-alpha AutoVac; TNFα AutoVacLatest Information Update: 12 Apr 2006
Price :
$50
*
At a glance
- Originator Pharmexa
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Psoriasis; Rheumatoid arthritis
- Discontinued Cachexia
Most Recent Events
- 12 Apr 2006 No development reported - Preclinical for Crohn's disease in Denmark (unspecified route)
- 12 Apr 2006 No development reported - Preclinical for Psoriasis in Denmark (unspecified route)
- 12 Apr 2006 No development reported - Preclinical for Rheumatoid arthritis in Denmark (unspecified route)